Diseases that dominate the 21st century need a 21st century approach in the way we design and conduct clinical trials. To meet this need, 乔治临床( George Clinical ) is primarily focused on large-scale studies with high-impact outcomes, particularly where smaller pre-registration trials need to be expanded to larger populations. 乔治临床( George Clinical ) has been […]
了解更多COPD is one of the world’s leading cause of death with prevalence ranging from 6% to 19% globally. This disease is particularly relevant for us in Asia-Pacific as risk factors such as smoking, biomass fuels, TB and air pollution are more prevalent than other regions. For example COPD prevalence in Chinese males is estimated to […]
了解更多One quarter of the world’s adult population suffers from hypertension, and although it has no obvious symptoms, it can lead to heart attacks, stroke, kidney failure and blindness. Despite this, there has been great uncertainty as to how intensively blood pressure should be lowered to obtain maximal benefit and minimize risks. Researchers from Australia, China, […]
了解更多The recent SAVOR-TIMI 53 (saxagliptin) and EXAMINE (alogliptin) trials recently reported the effects of the DPPIV inhibitor class of glucose lowering agents in people with diabetes. As required by the US FDA, both drugs were found not to increase cardiovascular risk, allowing the agents to be registered for use in that country. Good news, it would […]
了解更多As active contributors in research, sometimes it’s nice to take a step back and reflect how our work evolves from novel treatment to everyday practice. So much of how we choose to live our life now was determined by past evidence. But with the volume of information out there, it’s difficult to sift out the […]
了解更多
In testament to 乔治临床( George Clinical )’s operational experience and ability, we recently completed a Chinese registration trial for a mid-sized global pharmaceutical with excellent results
了解更多
乔治临床( George Clinical ), a leading Asia-Pacific CRO, is wholly owned by The George Institute, a world leading medical research institute focused on chronic disease. Our model sees us forming integrated project teams with our scientific thought leaders. The Neurological & Mental Health unit, one of the many divisions within The George Institute, has led […]
了解更多Effective management of diseases such as hypertension requires more than drug therapy, but also a change in diet and lifestyle.
了解更多A randomised, double-blind trial examining the effects of an ACE inhibitor-based blood pressure lowering regimen on the risk of stroke among patients with a history of cerebrovascular disease.
了解更多A randomised controlled double-blind study comparing the effects of saline versus albumin on mortality in 6,997 patients, with up to 30 days of follow-up. Saline vs Albumin Read more about the SAFE trial on The George Institute website This trial was completed under budget and ahead of schedule, with results published in The New England […]
了解更多
